Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 10% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Increases plasma osmolality, drawing water from tissues into the bloodstream, thereby reducing intracranial pressure and cerebral edema.
Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.
Reduction of intracranial pressure,Reduction of cerebral edema,Promotion of diuresis in oliguric phase of acute renal failure
Reduction of elevated intracranial pressure,Promotion of diuresis in acute renal failure,Reduction of intraocular pressure,Adjunct in treatment of acute oliguric renal failure,Management of cerebral edema
Initial: 0.25–1 g/kg (25–100 m L of 10% solution) IV over 30–60 minutes. May repeat every 6–12 hours if needed. Typical adult dose: 50–100 g IV. Maximum: 2 g/kg per dose.
Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.
Terminal half-life approximately 1.5 hours in normal renal function; prolonged in renal impairment (up to 36 hours in anuria).
Terminal elimination half-life is 0.25–1.5 hours; prolonged in renal impairment (up to 36 hours).
Primarily excreted unchanged by the kidneys; not metabolized.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration.
Primarily renal; >90% excreted unchanged in urine via glomerular filtration; <5% biliary/fecal.
Renal: >90% as unchanged drug; minimal biliary or fecal excretion.
Negligible (<10%); does not significantly bind to plasma proteins.
Negligible (<0.1%); no specific binding proteins.
Vd ~0.5 L/kg; distributes primarily in extracellular fluid, excluding cells.
0.2–0.5 L/kg; primarily confined to extracellular fluid; increases with dehydration.
Not applicable (administered intravenously only); bioavailability is 100% by IV route.
IV: 100%; oral: <10% due to poor absorption.
Contraindicated in anuria or severe renal impairment (GFR <10 m L/min). In patients with GFR 10–50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. Do not use if oliguria persists after test dose (0.2 g/kg IV over 3–5 minutes).
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. No specific dose for GFR >50 m L/min.
No specific Child-Pugh based adjustment. Use with caution in severe hepatic impairment due to potential for fluid overload and electrolyte disturbances. Monitor serum electrolytes and hepatic function.
No specific dose adjustment for hepatic impairment. Caution in patients with cirrhosis due to risk of fluid overload.
Oliguria: Test dose 0.2 g/kg (2 m L/kg of 10% solution) IV over 3–5 minutes. If urine output >40 m L/hr, maintenance dose: 0.25–1 g/kg (2.5–10 m L/kg) IV over 30–60 minutes every 6–12 hours. Maximum: 2 g/kg per dose. Reduce intracranial pressure: 0.25–1 g/kg IV over 30–60 minutes.
Children: For reduction of intracranial pressure, 0.25-1 g/kg as a 15-25% solution IV over 30-60 minutes. For diuresis, 0.5-2 g/kg as a 5-25% solution IV every 6-12 hours. Maximum dose 2 g/kg/dose.
Start at lower end of dosing range (0.25 g/kg) due to age-related decline in renal function. Monitor renal function, serum osmolarity, electrolytes (especially sodium and potassium), and fluid balance closely. Avoid use if GFR <50 m L/min unless benefit outweighs risk.
Elderly: Use lower doses and titrate carefully due to increased risk of fluid overload, electrolyte disturbances, and renal impairment. Monitor renal function and serum osmolarity. Start with the lower end of adult dosing range.
Not approved for use in patients with severe renal impairment, anuria, or intracranial hemorrhage with active bleeding.
None
Monitor renal function, fluid and electrolyte balance, and serum osmolality. Use caution in patients with cardiac or pulmonary congestion, and administer via a filter to prevent crystallization.
May cause volume expansion and pulmonary edema in patients with impaired renal function. Monitor renal function, serum electrolytes, and fluid balance. Avoid extravasation as it may cause tissue necrosis. Use with caution in patients with congestive heart failure or severe dehydration.
Anuria, severe renal impairment, pulmonary congestion, active intracranial hemorrhage, severe dehydration, known hypersensitivity to mannitol.
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, known hypersensitivity to mannitol.
No specific food interactions. Maintain adequate hydration as directed. Avoid excessive salt intake to minimize fluid retention.
No significant food interactions; maintain adequate hydration unless contraindicated.
Osmitrol 10% (mannitol) is a hyperosmolar agent. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. In first trimester, use only if clearly needed. In second and third trimesters, mannitol can cross the placenta and may cause fetal dehydration, electrolyte disturbances, and osmotic shifts. Risk cannot be excluded.
Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First trimester: theoretical risk from osmotic shifts. Second/third trimester: monitor for maternal hemodynamic changes (e.g., pulmonary edema) that may affect placental perfusion.
It is not known whether mannitol is excreted in human breast milk. No M/P ratio is available. Caution should be exercised when administered to a nursing woman. Consider the developmental and health benefits of breastfeeding alongside the mother's clinical need for the drug.
Unknown if excreted in human milk. No available data on M/P ratio. Consider benefits of breastfeeding vs. potential risk of osmotic effects or maternal dehydration. Caution advised.
Pregnancy increases glomerular filtration rate, which may enhance mannitol elimination, but dosage adjustments are not established. Maintain standard dosing (generally 50-200 g over 24 hours). Monitor clinical response and urine output. No routine pharmacokinetic-based dose adjustment recommended.
No specific dose adjustments recommended for pregnancy alone. Consider increased plasma volume in pregnancy; monitor for volume overload. Dose based on clinical response and renal function. Avoid rapid infusion.
Osmítrol 10% is a hyperosmotic agent used to reduce intracranial pressure and cerebral edema. Administer via IV infusion using an in-line filter to prevent particulate embolism. Monitor serum osmolarity and sodium levels; discontinue if osmolarity exceeds 320 m Osm/L. Ensure adequate hydration to avoid hypovolemia. Use with caution in patients with renal impairment, congestive heart failure, or pulmonary congestion. Crystallization may occur at low temperatures; warm to redissolve crystals before use.
Administer via large-bore IV; monitor serum osmolality and renal function; ensure urine output >30 m L/h; avoid extravasation; use with caution in patients with pulmonary congestion or CHF.
This medication is given intravenously to reduce swelling in the brain.,You may experience a headache, nausea, or increased thirst during infusion.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,You will be monitored with blood tests to check kidney function and electrolyte levels.,Avoid rapid position changes to prevent dizziness due to fluid shifts.,Do not stop this medication abruptly; follow your healthcare provider's instructions.
You may experience increased urination during treatment.,Report any chest pain, difficulty breathing, or swelling to your doctor immediately.,You may feel thirsty or have a dry mouth; this is expected.,Your blood sugar levels may be monitored if you have diabetes.,Avoid consuming large amounts of salt or salty foods.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 10% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10% IN PLASTIC CONTAINER, answered by our medical review team.
OSMITROL 10% IN WATER IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from tissues into the bloodstream, thereby reducing intracranial pressure and cerebral edema.. MANNITOL 10% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 10% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 10% IN WATER IN PLASTIC CONTAINER is: Initial: 0.25–1 g/kg (25–100 m L of 10% solution) IV over 30–60 minutes. May repeat every 6–12 hours if needed. Typical adult dose: 50–100 g IV. Maximum: 2 g/kg per dose.. The standard adult dose of MANNITOL 10% IN PLASTIC CONTAINER is: Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 10% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 10% IN WATER IN PLASTIC CONTAINER is classified as Category C. Osmitrol 10% (mannitol) is a hyperosmolar agent. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. In first trimester, us. MANNITOL 10% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.